Nuclisome--targeting the tumor cell nucleus.
The Nuclisome concept builds on a novel two-step targeting strategy with the aim to deliver short-range Auger-electron-emitting radionuclides to nuclear DNA of tumor cells. The concept is based on the use of Nuclisome-particles, i.e., tumor-targeted PEG-stabilized liposomes loaded with a unique DNA-intercalating compound that enables specific and effective delivery of radionuclides to DNA. The specific and potent two-step targeting leads to eradication of tumor cells while toxicity to normal organs is reduced to a minimum. Results of in vitro and in vivo studies point towards the Nuclisome concept as a promising strategy for the treatment of small tumor masses and, in particular, for the elimination of spread single cells and micrometastases.
Department of Radiology, Oncology and Radiation Sciences, Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden. Lars.Gedda@bms.uu.se
Lars
L
Gedda
Katarina
K
Edwards
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002467:Cell Nucleus / Q000235:genetics / Q000378:metabolism / Q000528:radiation effects*; D004273:DNA, Neoplasm / Q000528:radiation effects*; D006801:Humans; D008081:Liposomes; D051379:Mice; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011868:Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D008081:Liposomes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases